
    
      This randomized, open-label, multicenter, 2 parallel-group study evaluates the efficacy and
      safety of a weekly subcutaneously injected dose of albiglutide as compared with liraglutide.
      Subjects with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is
      inadequately controlled on their current regimen of metformin, thiazolidinedione,
      sulfonylurea, or any combination of these oral antidiabetics will be recruited into the
      study.
    
  